FDA Clears Way for Clinical Trial of HDP-101
Heidelberg Pharma has been cleared in the U.S.
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
Under-the-skin Velcade Found to Work Better in Farydak Triple Combo
Using an under-the-skin formulation of Velcade (bortezomib), in…
Phase 3 Trial of ATG-010 (Xpovio) for Advanced Myeloma Opens in China
China’s regulatory agency has approved the start of a…
EMA Plans Speedy Review of Cilta-cel, CAR T-cell Therapy for Advanced Myeloma
An accelerated review will be given an application for…
EU Committee Supports Nexpovio for Heavily Treated Myeloma Patients
A combination of Nexpovio (selinexor) and the corticosteroid…
Dosing Begins in Phase 1 Trial of CERC-007
Cerecor has dosed the first patient in a Phase…
